Molecular targets in cancer therapy: the Ron approach
The receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2011-12-01
|
Series: | Oncology Reviews |
Subjects: | |
Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/158 |
id |
doaj-560573f191eb4991a92650aa929213e1 |
---|---|
record_format |
Article |
spelling |
doaj-560573f191eb4991a92650aa929213e12020-11-25T01:24:13ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652011-12-0114Molecular targets in cancer therapy: the Ron approachSerena Germano0Giovanni Gaudino1DISCAFF Department and DFB Center, University of Piemonte Orientale “A. Avogadro”, NovaraDISCAFF Department and DFB Center, University of Piemonte Orientale “A. Avogadro”, NovaraThe receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved in tumor progression and metastasis. Growing evidence indicates that Ron is abnormally expressed and activated in certain types of primary epithelial cancers (i.e. breast, colon, lung, pancreas, bladder and thyroid), where it critically contributes to the maintenance of tumorigenic and invasive phenotype. Furthermore, a positive association between aberrant Ron expression and aggressive biological indicators as well as a worse clinical outcome have been reported in breast, bladder and thyroid carcinomas. Different approaches have proved effective in targeting receptor activation/expression both in vitro and in animal models, leading to reversion of the tumorigenic phenotype. Altogether these results show that Ron is an attractive molecular target for clinical intervention.http://www.oncologyreviews.org/index.php/or/article/view/158Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Serena Germano Giovanni Gaudino |
spellingShingle |
Serena Germano Giovanni Gaudino Molecular targets in cancer therapy: the Ron approach Oncology Reviews Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers |
author_facet |
Serena Germano Giovanni Gaudino |
author_sort |
Serena Germano |
title |
Molecular targets in cancer therapy: the Ron approach |
title_short |
Molecular targets in cancer therapy: the Ron approach |
title_full |
Molecular targets in cancer therapy: the Ron approach |
title_fullStr |
Molecular targets in cancer therapy: the Ron approach |
title_full_unstemmed |
Molecular targets in cancer therapy: the Ron approach |
title_sort |
molecular targets in cancer therapy: the ron approach |
publisher |
PAGEPress Publications |
series |
Oncology Reviews |
issn |
1970-5557 1970-5565 |
publishDate |
2011-12-01 |
description |
The receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved in tumor progression and metastasis. Growing evidence indicates that Ron is abnormally expressed and activated in certain types of primary epithelial cancers (i.e. breast, colon, lung, pancreas, bladder and thyroid), where it critically contributes to the maintenance of tumorigenic and invasive phenotype. Furthermore, a positive association between aberrant Ron expression and aggressive biological indicators as well as a worse clinical outcome have been reported in breast, bladder and thyroid carcinomas. Different approaches have proved effective in targeting receptor activation/expression both in vitro and in animal models, leading to reversion of the tumorigenic phenotype. Altogether these results show that Ron is an attractive molecular target for clinical intervention. |
topic |
Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers |
url |
http://www.oncologyreviews.org/index.php/or/article/view/158 |
work_keys_str_mv |
AT serenagermano moleculartargetsincancertherapytheronapproach AT giovannigaudino moleculartargetsincancertherapytheronapproach |
_version_ |
1725118246246416384 |